Cruz GAA, Reyes ZMG, Ramos GMV, García MS, Quintero AG, Rojas MPR, Valdez MMY

Language: Spanish
References: 14
Page: 238-243
PDF size: 606.87 Kb.

ABSTRACT

Background: about 180 million people worldwide are chronically infected by hepatitis C. This condition is the leading cause of liver cirrhosis and hepatocellular carcinoma and the main indications for liver transplantation in the United States.
Objective: To determine the prevalence of infection with hepatitis ¨C¨ in blood donors rejected by some risk factors that come to the blood bank’s medical center of the November 20 federal ISSSTE and compare the results with the national average.
Material and Methods: We performed a cross-sectional study which included a total of 500 donors of both sexes declined by some risk factors for HCV occurred between April 2008 and April 2009 were applied a questionnaire and informed consent rejected those subjects with a factor risk is performed by a rapid immunoassay test for detection of HCV. Were a total of 500 questionnaires in subjects refused blood bank in which they detected a total of 100 subjects with risk factors for HCV with which they perform a rapid test for detection of viruses, the results have been obtained and perform statistical analysis.
Results: The prevalence of hepatitis virus carriers ‘’C’’ was 1.0% (5 patients) value of P (0.4,95% CI 0.902,1.098), representing a 0.6% in men with a total of 3 patients and a 0.4% in women with a total of 2 patients, with ages ranging from 25 to 64years.The predominant risk factor for HCV were transfusions before 1992 with a total of 3patients (60%), surgery and transfusion before 1992, 1 patient (20%), risk of work (by contaminated needle punction) 1 patient (20%).

REFERENCES

1. World Health Organization. Initiative for Vaccine Research. Hepatitis C. (Accessed April 6, 2009.) http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.)

2. Dieterich D, Peter K. Guías de manejo de hepatitis C. New York: Thompson PLM, 2006.

3. Hernández-Lugo MI, Contreras AM. Hepatitis C en el contexto de la donación sanguínea. Rev Med Inst Mex Seguro Soc 2006;44(2):3-6.

4. Vera de León L, Juárez Navarro JA, Díaz Gómez M, Méndez Navarro J, et al. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005;70(1):25-32.

5. Alter MJ. Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. Epidemiology of Hepatitis C in the west. Semin Liver Dis 1995;15:5-14

6. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, et al. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827-1838.

7. Feldman M, Lawrence S, Friedman R, Lawrence J. Sleisenger and Fordtran´s Gastrointestinal and Liver disease. 8th ed. New York: Elsevier, 2006.

8. Contreras AM. Anticuerpos a Hepatitis C: ¿verdadero o falso positivo? Nuevas estrategias de diagnóstico. Rev Inv Clin 2006;58(2):153-160.

9. Institutos Nacionales de Salud y Asociación Mexicana de Hepatología. National Concensus in hepatitis C. Ann Hepatol 2002;3:148-154.

10. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: and overview world. Gastroenterology 2007;13:2467-2478.

11. Stribling R, Sussman N, Vierling JM, Treatment of hepatitis C Infection. Gastroenterol Clin N Am 2006;35(2):463-486.

12. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003;7(1):127-137.

13. Garcia-Retortillo M , Forns X. Genomic variability and natural history of hepatitis C virus infection. Gastroenterol Hepatol 2002;25(8):514-520.

14. Schiff¨s ER, Michael F, Willis C, et al. Diseases of the liver. Atlanta: Marban, 2007; 812.